Andrea (Flynn) Franson, MD, MS
Clinical Associate Professor of Pediatrics
Fellowship Director of Pediatric Hematology/Oncology
Medical School
Department of Pediatrics
D4202 MPB
Ann Arbor, MI 48109-5718
D4202 MPB
Ann Arbor, MI 48109-5718
Available to mentor
Andrea (Flynn) Franson, MD, MS
Clinical Associate Professor
Manage Your Profile
About
Dr. Andrea (Flynn) Franson is a Pediatric Oncologist in the Department of Pediatrics at the University of Michigan. She received her bachelor’s degree from Rensselaer Polytechnic Institute in Troy, New York and her medical degree from the University of Michigan Medical School. She completed her residency in Pediatrics and fellowship in Pediatric Hematology/Oncology at the Children’s Hospital of Philadelphia (CHOP). During fellowship, she earned a master’s degree in Pharmacology from Thomas Jefferson University. She joined as faculty at the University of Michigan in 2019.
Links
twitter
Qualifications
-
FellowshipChildren's Hospital of Philadelphia, Pediatric Hematology and Oncology, Philadelphia, United States
2014 - 2017
-
Clinical Pharmacology FellowThomas Jefferson University, Pharmacology and Experimental Therapeutics, Philadelphia, United States
2015 - 2017
-
ResidencyChildren's Hospital of Philadelphia, Pediatrics, Philadelphia, United States
2012 - 2014
-
InternshipChildren's Hospital of Philadelphia, Pediatrics, Philadelphia, United States
2011 - 2012
-
MS, PharmacologyThomas Jefferson University, 130 S. Ninth Street, Suite 100, Philadelphia, PA, 19107, United States
2015 - 2017
-
MDUniversity of Michigan, Ann Arbor, MI, United States
2007 - 2011
-
BSRensselaer Polytechnic Institute, Troy, NY, United States
2003 - 2007
Center Memberships
-
Center MemberRogel Cancer Center
Research Overview
Broadly, Dr. Franson's research interests are in the clinical translation of promising therapeutic approaches from the lab into pediatric patients with high-risk brain tumors. She collaborates with several basic science laboratories on campus to move successful compounds or immunotherapies into pediatric and AYA focused clinical trials, with an interest in novel clinical trial designs and the use of PK/PD-informed dosing.
Recent Publications
-
Peterson ER, Parsels LA, Li Z, Zhao X, Hess LD, Guo Y, Messinger D, Parsels JD, Wang Z, Qin T, Valvo VM, Franson AT, Castro MG, Yadav VN, Lawrence TS, Koschmann C, Zhang Q, Wahl DR, Morgan MA. Mol Cancer Ther, 2026 Jul 14;Journal ArticleH3K27M enhances basal ATM signaling but is not required for radiosensitization of diffuse midline glioma via ATM inhibition with AZD1390.
DOI:10.1158/1535-7163.MCT-24-1019 PMID: 42444560 -
Laslo D, Nguyen TPD, Lerman B, Stoller S, Knowles T, Suhami D, Mir N, Avval AH, Carrion AW, Kline C, Franson A, Müller T, Rauschecker A, Jutzeler C, Mueller S, Brüningk S. Neuro-Oncology Pediatrics, 2026 Jun 25; 2 (Supplement_1): wuag026.442Journal ArticleID #1008 Trajectory-Based Modeling For Pre-Treatment Prediction of Radiotherapy Response in Diffuse Midline Glioma
DOI:10.1093/neuped/wuag026.442 -
Savary C, Vo T, Jackson E, Persson M, Douglas A, McEwen H, McLachlan T, Kline C, Franson A, Waszak S, Nazarian J, Koschmann C, Mueller S, Dun M. Neuro-Oncology Pediatrics, 2026 Jun 25; 2 (Supplement_1): wuag026.267Journal ArticleID #666 Deciphering cellular sates associated with response to dordaviprone (ONC201) in diffuse midline glioma patients from the PNOC022 clinical trial
DOI:10.1093/neuped/wuag026.267 -
Grotewold N, Kandiraju S, Kumar-Sinha C, Robertson DR, Wu Y-M, Vo J, Chinnaiyan A, Mody R, Upadhyaya S, Jacobs MF, Franson A. 2026 May 7;Proceeding / Abstract / PosterGermling findings of cancer risk predisposition syndromes in pediatric and young adult patients with high grade glioma
-
Fathi Kazerooni A, Jiang Z, Gandhi D, Khalili N, Liu X, Tu W, Ware JB, Familiar AM, Vunnava B, Zapaishchykova A, McAllister AS, Sanchez-Montano M, Sheth N, Nandolia KK, Lai HA, Pavaine J, Prabhu SP, Haldar D, Varshochi S, Bagheri S, Anderson H, Haldar S, Khalili N, Gottipati A, Shaikh IS, Castellino E, Mangoli A, Gohil H, Maleki N, Low J, Hummel T, Packer RJ, Franson A, Storm PB, Bakas S, Calabrese E, Aboian M, de Blank P, Kann BH, Rood B, Resnick AC, Nabavizadeh A, Vossough A, Linguraru MG. Radiol Artif Intell, 2026 Apr 29; e250902Journal ArticleMulti-Institutional Annotated Multiparametric MRI Dataset of Pediatric High-Grade Gliomas.
DOI:10.1148/ryai.250902 PMID: 42053414 -
Kline C, Landi D, Khuong-Quang D-A, Nysom K, Kilburn LB, Waanders AJ, Perreault S, Mueller S, McCowage G, Driever PH, Leary SES, Ziegler DS, Kang HJ, Witt O, Baxter PA, Bailey S, Chi SN, Han JW, Abdelbaki MS, Hassall TE, Franson AT, Hargrave D, Toledano H, Oren MY, Jabado N, Gottardo NG, Gerber NU, Renzi S, Segal D, Tan EEK, Oren L, Whipple NS, Hansford JR, Pehlivan K, Zhang J, Manley P, Ott L, Barry E, Maher JC, van der Lugt J. Neuro-Oncology Pediatrics, 2026 Apr 24;Journal ArticleClinical stability after tovorafenib treatment in patients with relapsed/refractory pediatric low-grade glioma: Updated results from the phase 2 FIREFLY-1 trial
DOI:10.1093/neuped/wuag022 -
Kotch C, Avery RA, Franson AT, Hargrave D, Brossier NM, Bornhorst M, Rangnath S, Nevel KS, Robison NJ, Liu GT, Fisher MJ, de Blank P. Neuro-Oncology Pediatrics, 2026 Feb 28; 2 (1):Journal ArticleClinical safety and efficacy of bevacizumab in combination with mitogen-activated protein kinase kinase inhibitor therapy for glioma: a retrospective analysis
DOI:10.1093/neuped/wuag011 -
Natarajan SK, Lum J, Skeans JH, Nenwani M, Eyunni S, Mota M, Bayliss JM, Deogharkar A, Hamanishi ET, Pun M, Sweha SR, Hoffman S, Young E, Zhang Q, Mehta R, Animasahun O, Narayanan P, Sunil S, Parolia A, Sajjakulnukit P, Panwalkar P, Doherty R, Clausen M, Dang D, Hawes D, Yang F, Santi M, Judkins AR, Wilson Y, Vigil T, Franson A, Mortensen RM, Ozawa T, Griesinger A, Holland EC, Foreman NK, Michealraj KA, Agnihotri S, Taylor M, Gilbertson RJ, Koschmann C, Chinnaiyan AM, Lyssiotis CA, Nagrath D, Venneti S. Nature, 2026 Feb 4;Journal ArticleZFTA-RELA ependymomas make itaconate to epigenetically drive fusion expression.
DOI:10.1038/s41586-025-10005-1 PMID: 41639460
Featured News & Stories
Health Lab
Path forward for glioblastoma treatment
Experts in brain cancer outline current discoveries and offer a path of hope for glioblastoma treatment
Health Lab
4-year-old pediatric brain cancer patient wins over his care team with cheerful personality
Pediatric cancer patient at Michigan Medicine was diagnosed with ATRT and underwent chemotherapy and radiation. Four years later, he’s doing well.
Health Lab
New clinical trials for pediatric brain tumors
Brain and spinal cord tumors account for one in four childhood cancers. Although 75% of children survive for at least five years after being diagnosed, many patients have recurrent tumors that cannot be cured. Andrea Franson discusses current therapies for pediatric brain tumors, how viruses can be used to target tumor cells and the new phase 1 trial that started in May 2025.
Department News
Department of Pediatrics Faculty Promotions
U-M faculty across pediatrics, cardiology, psychology & more were promoted in 2025, recognizing excellence in clinical and academic leadership.
Department News
New clinical trials for pediatric brain tumors
Pediatric brain tumors are tough to treat—new trials use viruses to boost immunity and target recurring cancer cells. Hope is rising.
Illuminate
A Path of Hope for Glioblastoma Treatment
The University of Michigan has become a world-renowned institution for treating aggressive brain tumors. From identifying deadly tumors sooner, understanding the biology of how and why they grow, and uncovering promising new treatments, Rogel researchers are carving a path that creates hope for patients, becoming a hub of innovation in the process.
